USFDA Makes Three Observations for Pharmaceutical Company Stride Shasun’s South Bengaluru plant

Indian pharmaceutical company Strides Shasun has received three observations for its South Bengaluru plant from the United States Food & Drugs Administration (USFDA).

The USFDA is authorised to perform inspections and to document and communicate concerns discovered during these inspections, form 483 is used.

Any company which receives form 483, has to respond to the USFDA, addressing each item, indicating agreement and either providing a timeline for correction or requesting clarification of what the USFDA requires.

Trading at Rs 936 per share, lower by Rs 20 per share or 2.1% at 1035 hours. Stock of the company was losing ground on the NSE.